Free Trial

Teza Capital Management LLC Purchases Shares of 38,090 Doximity, Inc. (NASDAQ:DOCS)

Doximity logo with Medical background

Teza Capital Management LLC acquired a new position in Doximity, Inc. (NASDAQ:DOCS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 38,090 shares of the company's stock, valued at approximately $2,034,000.

Several other institutional investors and hedge funds have also recently modified their holdings of DOCS. FMR LLC increased its position in shares of Doximity by 37.6% during the fourth quarter. FMR LLC now owns 9,409,313 shares of the company's stock valued at $502,363,000 after buying an additional 2,571,580 shares during the period. Arrowstreet Capital Limited Partnership boosted its position in Doximity by 708.7% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,510,416 shares of the company's stock valued at $80,641,000 after acquiring an additional 1,323,634 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Doximity by 525.1% during the 4th quarter. Invesco Ltd. now owns 1,272,403 shares of the company's stock worth $67,934,000 after acquiring an additional 1,068,849 shares during the period. Franklin Resources Inc. raised its position in shares of Doximity by 1,178.3% in the 4th quarter. Franklin Resources Inc. now owns 1,062,211 shares of the company's stock worth $56,711,000 after acquiring an additional 979,113 shares in the last quarter. Finally, Fundsmith LLP purchased a new position in shares of Doximity in the 4th quarter valued at approximately $37,934,000. 87.19% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

DOCS has been the topic of several recent research reports. Robert W. Baird reduced their price target on Doximity from $87.00 to $65.00 and set an "outperform" rating on the stock in a research note on Tuesday. Needham & Company LLC dropped their target price on shares of Doximity from $82.00 to $67.00 and set a "buy" rating on the stock in a report on Friday, May 16th. Mizuho decreased their price target on shares of Doximity from $65.00 to $60.00 and set a "neutral" rating for the company in a research note on Friday, May 16th. William Blair reissued an "outperform" rating on shares of Doximity in a research report on Friday, May 16th. Finally, The Goldman Sachs Group set a $50.00 price objective on shares of Doximity and gave the stock a "neutral" rating in a research note on Wednesday. Eleven investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Doximity presently has an average rating of "Moderate Buy" and an average target price of $61.22.

View Our Latest Stock Report on DOCS

Doximity Stock Performance

Shares of NASDAQ:DOCS traded down $0.33 during trading on Friday, reaching $50.93. 614,789 shares of the stock traded hands, compared to its average volume of 2,089,584. The stock has a market cap of $9.51 billion, a P/E ratio of 50.81, a price-to-earnings-growth ratio of 4.10 and a beta of 1.41. The stock has a 50-day moving average of $56.56 and a two-hundred day moving average of $58.01. Doximity, Inc. has a 52-week low of $25.00 and a 52-week high of $85.21.

Doximity (NASDAQ:DOCS - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The company reported $0.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.11. Doximity had a return on equity of 21.75% and a net margin of 36.60%. Doximity's revenue was up 17.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.25 EPS. Sell-side analysts expect that Doximity, Inc. will post 0.99 earnings per share for the current year.

Insider Activity

In other news, CFO Anna Bryson sold 45,000 shares of Doximity stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $57.23, for a total value of $2,575,350.00. Following the completion of the sale, the chief financial officer now directly owns 357,165 shares in the company, valued at $20,440,552.95. The trade was a 11.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Kira Scherer Wampler sold 2,000 shares of the business's stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $56.93, for a total transaction of $113,860.00. Following the transaction, the director now directly owns 16,618 shares of the company's stock, valued at $946,062.74. The trade was a 10.74% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 37.40% of the company's stock.

Doximity Company Profile

(Free Report)

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.

Read More

Institutional Ownership by Quarter for Doximity (NASDAQ:DOCS)

Should You Invest $1,000 in Doximity Right Now?

Before you consider Doximity, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Doximity wasn't on the list.

While Doximity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Tech Stocks Insiders Are Buying: Speculative Plays for June
3 Defense Stocks Set to Crush the S&P This Summer
Analysts Are Watching These 4 Penny Stocks—You Should Too

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines